Semaglutide brand names in the United States are Ozempic, Wegovy, and Rybelsus. All three contain semaglutide and are made by Novo Nordisk, but they are not interchangeable labels for one product. Ozempic is primarily a once-weekly injectable for adults with type 2 diabetes. Wegovy is the weight-management brand and now comes as a weekly injection or daily tablet. Rybelsus is a daily oral tablet for adults with type 2 diabetes. There is no FDA-approved generic semaglutide in the U.S. as of August 17, 2026.
Semaglutide brand names at a glance
| Brand | Manufacturer | What the FDA has approved it for | How it is supplied |
|---|---|---|---|
| Ozempic | Novo Nordisk | Glycemic control in adults with type 2 diabetes; lower risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; lower risk of specified kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease | Once-weekly subcutaneous injection in single-patient-use pens or single-dose prefilled syringes |
| Wegovy | Novo Nordisk | Long-term weight reduction in qualifying adults and, for the injection, adolescents 12 and older with obesity; lower major cardiovascular-event risk in adults with established cardiovascular disease and overweight or obesity; the injection also has accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis in adults | Once-weekly subcutaneous injection, including the Wegovy HD presentation, or once-daily oral tablets for adults |
| Rybelsus | Novo Nordisk | Glycemic control in adults with type 2 diabetes; lower risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for them | Once-daily oral tablets in bottles of 30 |
Those are indication summaries, not a guide for choosing a product. Age, diagnosis, cardiovascular and kidney history, other medications, contraindications, coverage, and formulation preference all change the clinical decision. The current labels also make two older shortcuts inaccurate: Wegovy is no longer injection-only, and Rybelsus is no longer limited to a glycemic-control indication.
Wegovy HD is a higher-strength Wegovy injection presentation, not a fourth molecule. It sits under the Wegovy name. The broader point is that a brand identifies a specific reviewed product, formulation, label, and manufacturer—not merely an ingredient.
Why the semaglutide brand name changes the answer
A prescription for Ozempic and a prescription for Wegovy can contain the same molecule while targeting different labeled populations. Ozempic's label centers on type 2 diabetes and related cardiovascular and kidney outcomes. Wegovy's label centers on long-term weight management, cardiovascular-risk reduction in a defined population, and an accelerated-approval MASH indication for the injectable product. Rybelsus packages semaglutide as a daily oral diabetes medicine.
That distinction matters when someone asks whether Ozempic is “the same as” Wegovy. Chemically, the active molecule is semaglutide. Clinically and regulatorily, the finished products differ in formulation, supply device, labeled use, and supporting evidence. They should not be treated as automatic substitutes. For the underlying pharmacology, see how GLP-1 therapy fits metabolic support; for practical adverse-effect context, see semaglutide side effects.
The trials behind Ozempic, Wegovy, and Rybelsus
The trial names help explain why the labels diverged. In SUSTAIN-6, published in the New England Journal of Medicine in 2016, 3,297 adults with type 2 diabetes at high cardiovascular risk received once-weekly injectable semaglutide or placebo. The primary cardiovascular outcome occurred in 6.6% versus 8.9%, respectively (Marso et al., 2016). That evidence belongs to a diabetes population and informs the Ozempic story; it should not be repackaged as a universal claim about every semaglutide product.
Wegovy's weight-management evidence comes from the STEP program. In STEP 1, published in the New England Journal of Medicine in 2021, mean body-weight change at 68 weeks was −14.9% with once-weekly injectable semaglutide and −2.4% with placebo, both alongside lifestyle intervention (Wilding et al., 2021). The later SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but without diabetes. Major cardiovascular events occurred in 6.5% with semaglutide and 8.0% with placebo over a mean follow-up of 39.8 months (Lincoff et al., NEJM 2023).
Rybelsus has its own oral-formulation evidence. In the SOUL trial, published in the New England Journal of Medicine in 2025, 9,650 adults with type 2 diabetes plus atherosclerotic cardiovascular disease, chronic kidney disease, or both were randomized to oral semaglutide or placebo. Major cardiovascular events occurred in 12.0% and 13.8%, respectively, over a mean 47.5 months (McGuire et al., 2025). These are trial averages in defined populations, not predictions for an individual.
Is compounded semaglutide a brand name?
Compounded semaglutide is not Ozempic, Wegovy, Rybelsus, or a generic version of any of them. A brand name belongs to a specific manufacturer and reviewed drug application. A compounded preparation is not a generic: a true generic must receive its own FDA approval and meet the agency's standards for sameness and bioequivalence. The FDA's Orange Book database showed no approved semaglutide generic as of August 17, 2026. The agency published draft semaglutide guidance for prospective generic applicants in July 2026, but development guidance is not an approval.
Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA likewise says a compounded medication should not be described as a generic or as the same as an approved drug (FDA guidance for telehealth companies). A licensed provider may still prescribe a compounded formulation when clinically appropriate; that decision is between the patient and the doctor.
What to check when a listing says only “semaglutide”
The ingredient name alone leaves out the part that determines what is actually being offered. A clear listing should identify the brand or state plainly that the medication is compounded, name the dosage form, identify the dispensing pharmacy as licensed, and require a prescription. It should not borrow Ozempic, Wegovy, or Rybelsus branding for a compounded vial.
The schedule is also product-specific. Brand pens, brand tablets, and compounded vials are not handled as one format. Semaglutide dosage schedules explains how a prescriber approaches titration without turning a label into a self-directed protocol.
How Promise handles the distinction
Promise identifies its product as compounded semaglutide rather than presenting it as a Novo Nordisk brand. A licensed provider reviews every request and prescribes only when semaglutide is medically appropriate; not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares and dispenses the medication.
That accountability is the meaningful difference between a prescription route and a vial advertised online with a famous brand name loosely attached. The label should tell the truth about the product, and a clinician should be responsible for deciding whether it fits the patient.